New drugs for the functional cure of hepatitis B： Focusing on antisense oligonucleotides and small interfering RNAs
- VernacularTitle:乙型肝炎功能性治愈新药： 聚焦反义寡核苷酸和小干扰RNA
- Author:
Xieer LIANG
1
;
Zhihong LIU
1
;
Jinlin HOU
1
Author Information
- Publication Type:Journal Article
- Keywords: Hepatitis B; Oligonucleotides， Antisense; RNA， Small Interfering; Hepatitis B Surface Antigens; Functional Cure
- From: Journal of Clinical Hepatology 2025;41(1):7-14
- CountryChina
- Language:Chinese
- Abstract: Existing nucleos（t）ide analogues and pegylated interferon exhibit limited efficacy in the functional cure of hepatitis B. Recently， small nucleic acid drugs， such as antisense oligonucleotides and small interfering RNAs， have brought unprecedented breakthroughs in the functional cure of hepatitis B with their brand-new mechanisms of action and remarkable efficacy in early clinical studies. Small nucleic acid drugs， such as antisense oligonucleotides and small interfering RNAs， can reduce the level of HBsAg and strive to achieve HBsAg seroclearance. The reduction in HBsAg may restore the hepatitis B-specific immune function of the body to some extent and may further transform the simple clearance of HBsAg into hard endpoints with clinical value， such as reducing hepatitis B-related liver events. By meticulously analyzing the dynamic trajectory of HBsAg alterations within the context of new drug applications and further optimizing combined treatment strategies and regimens， it is expected to transform the functional cure of hepatitis B into the ultimate goal of improving survival rates and quality of life.
